Angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which were initially blamed for the poor outcome of the disease, do not affect the clinical outcome of patients with COVID-19 [45]. This evidence concerns the gene ACE and COVID-19.